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Abstract
Background: In our earlier genome-wide association study on Stevens-Johnson Syndrome (SJS) and its severe variant, toxic
epidermal necrolysis (TEN), we found that in Japanese patients with these severe ocular surface complications there was an
association with prostaglandin E receptor 3 (EP3) gene (PTGER3) polymorphisms. We also reported that EP3 is dominantly
expressed in the ocular surface-, especially the conjunctival epithelium, and suggested that EP3 in the conjunctival
epithelium may down-regulate ocular surface inflammation. In the current study we investigated the expression of EP3
protein in the conjunctiva of patients with various ocular surface diseases such as SJS/TEN, chemical eye burns, Mooren’s
ulcers, and ocular cicatricial pemphigoid (OCP).
Methodology/Principal Findings: Conjunctival tissues were obtained from patients undergoing surgical reconstruction of
the ocular surface due to SJS/TEN, chemical eye burns, and OCP, and from patients with Mooren’s ulcers treated by
resection of the inflammatory conjunctiva. The controls were nearly normal human conjunctival tissues acquired at surgery
for conjunctivochalasis. We performed immunohistological analysis of the EP3 protein and evaluated the immunohisto-
logical staining of EP3 protein in the conjunctival epithelium of patients with ocular surface diseases. EP3 was expressed in
the conjunctival epithelium of patients with chemical eye burns and Mooren’s ulcer and in normal human conjunctival
epithelium. However, it was markedly down-regulated in the conjunctival epithelium of SJS/TEN and OCP patients.
Conclusions: We posit an association between the down-regulation of EP3 in conjunctival epithelium and the pathogenesis
and pathology of SJS/TEN and OCP, and suggest a common mechanism(s) in the pathology of these diseases. The
examination of EP3 protein expression in conjunctival epithelium may aid in the differential diagnosis of various ocular
surface diseases.
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Introduction
Prostanoids are comprised of prostaglandins (PGs) and throm-
boxanes (TXs). They are lipid mediators that form in response to
various stimuli and include PGD2, PGE2, PGF2a, PGI2, and TXA2.
They are released extracellularly immediately after their synthesis
and they act by binding to a G-protein-coupled rhodopsin-type
receptor on the surface of target cells. There are 8 types of
prostanoid receptors that are conserved in mammals from mouse to
human: the PGD receptor (DP), 4 subtypes of the PGE receptor
(EP1, EP2, EP3, and EP4), the PGF receptor (FP), the PGI receptor
(IP), and the TXA receptor (TP) [1].
Stevens-Johnson syndrome (SJS) and its severe variant, toxic
epidermal necrolysis (TEN) are acute inflammatory vesiculobul-
lous reactions of the skin and mucosa including the ocular surface
[2]. In our earlier genome-wide association study in Japanese SJS/
TEN patients with severe ocular surface complications we found
associations with 6 single nucleotide polymorphisms (SNPs) in the
prostaglandin E receptor 3 (EP3) gene (PTGER3) and we
documented that compared with the controls, EP3 expression
was markedly reduced in the conjunctival epithelium of SJS/TEN
patients with severe ocular complications [3]. Others reported that
the PGE2-EP3 signaling pathway negatively regulates allergic
reactions in a murine allergic asthma model [4] and that it inhibits
keratinocyte activation and exerts anti-inflammatory actions in
mouse contact hypersensitivity [5]. We also showed that EP3 is
dominantly expressed in the ocular surface-, especially the
conjunctival epithelium, and that PGE2 acts as a ligand for EP3
in the conjunctival epithelium and down-regulates the progression
of murine experimental allergic conjunctivitis [6]. In addition, we
reported that an EP3 agonist suppressed the production of CCL5,
CXCL10, CXCL11, and IL-6 in response to polyI:C stimulation
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conjunctival epithelium may down-regulate ocular surface inflam-
mation [7].
In the current study we investigated the expression of EP3
protein in the conjunctiva of patients with various ocular surface
diseases such as SJS/TEN, chemical eye burns, Mooren’s ulcers,
and ocular cicatricial pemphigoid (OCP).
Materials and Methods
Human conjunctival tissues
This study was approved by the Institutional Review Board of
Kyoto Prefectural University of Medicine, Kyoto, Japan. All
experiments were conducted in accordance with the principles set
forth in the Helsinki Declaration.
Figure 1. Immunohistological analysis of prostaglandin E receptor subtype EP3 in the conjunctival epithelium of the controls and
SJS/TEN patients. A. Nearly normal conjunctival tissues from patients with conjunctivochalasis. B. Normal conjunctival tissue. C. Keratinized
conjunctival tissues of SJS/TEN patients in the chronic stage. D. Non-keratinized conjunctival tissues of SJS/TEN patients in the sub-acute stage. E.
Non-keratinized conjunctival tissues of SJS/TEN patients in the chronic stage. F. Visibly normal conjunctival tissue of an SJS/TEN patient with minor
ocular sequelae (dry eye). C-F. The 3
rd lane shows the ocular surface of SJS/TEN patients. Each scale bar represents a length of 100 mm.
doi:10.1371/journal.pone.0025209.g001
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human conjunctival tissues acquired at surgery for conjunctivo-
chalasis and one sample of normal conjunctival tissue acquired at
limbal dermoid resection. Conjunctival tissues were also obtained
from patients undergoing surgical reconstruction of the ocular
surface due to SJS/TEN (n=7), chemical eye burns (n=3), OCP
(n=3), severe graft versus host disease (GVHD) (n=1), pseudo-
OCP (n=1) and pterygium (PTG) (n=1), from patients with
Mooren’s ulcers treated by resection of the inflammatory
conjunctiva (n=4), and from a patient with a giant papilla due
to allergic vernal conjunctivitis. One conjunctival tissue sample
was obtained from an SJS/TEN patient who did not require
ocular surface reconstruction because ocular sequelae were minor
(dry eye); this sample derived from additional unnecessary
conjunctiva harvested just after cataract surgery.
Immunohistochemistry
For EP3 staining we used rabbit polyclonal antibody to EP3
(Cayman Chemical Co., Ann Arbor, MI) [3,6]. We previously checked
and confirmed the EP3 specificity of this antibody using conjunctiva
from EP3KO mice [6]. Further confirmation was by immunoblot
analysis (Fig. S1). The secondary antibody (Biotin-SP-conjugated
AffiniPure F(ab’)2 fragment donkey anti-rabbit IgG (H+L), 1:500
dilution; Jackson Immuno Research, Baltimore, MD) was applied for
30 min,then VECTASTAIN ABC reagent (Vector Laboratories, Inc.,
Burlingame, CA) was added for increased sensitivity with peroxidase
substrate solution (DAB substrate kit; Vector) as a chromogenic
substrate.
Evaluation of staining intensity using ImageJ software
and down-regulation score
We converted the multi-color pictures into black and white
pictures, and measured the gray value in the vertical line of the
conjunctival epithelium. Then we recorded the average gray value
on an intensity score from 5 to 16 (e.g. an average gray value of
100 was scored as 10). We also recorded the degree of down-
regulation where "–" = intensity score 12–16, "+" = intensity
score 8–11, and "++" = intensity score 5–7.
Results
As reported elsewhere [3], EP3 protein was detected in the
nearly normal conjunctival epithelium from patients with
conjunctivochalasis (Fig. 1A) and in the normal conjunctival
Figure 2. Immunohistological analysis of prostaglandin E receptor subtype EP3 in the conjunctival epithelium of patients with
chemical eye burn and active Mooren’s ulcer. A. Conjunctival tissues of patients with chemical eye burn requiring ocular surface reconstruction.
B. Inflammatory conjunctival tissues of patients with active Mooren’s ulcer requiring resection of the inflammatory conjunctiva. The 3
rd lane shows
the ocular surface of patients. Each scale bar represents a length of 100 mm.
doi:10.1371/journal.pone.0025209.g002
EP3 Expression and Ocular Surface Disorders
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25209epithelium sample (Fig. 1B), but not in keratinized conjunctival
epithelium from SJS/TEN patients in the chronic stage (Fig. 1C).
When we examined non-keratinized conjunctival epithelium from
SJS/TEN patients in the sub-acute- or chronic stage (Figs. 1D, 1E)
we found that EP3 was markedly down-regulated. Interestingly,
even in the conjunctival epithelium from the SJS/TEN patient
manifesting only dry eye, EP3 was greatly down-regulated (Fig. 1F).
Comparison with conjunctival tissues from patients with
chemical eye burn showed that although ocular surface findings
were similar, EP3 protein was detected in the conjunctival
epithelium of 3 patients with chemical eye burn as well as in
control conjunctival epithelium from conjunctivochalasis patients
(Fig. 2A). We also detected EP3 protein in conjunctival epithelium
from 4 patients with Mooren’s ulcer, however, it appeared to be
somewhat down-regulated (Fig. 2B).
Next we examined conjunctival tissues from 3 patients with
OCP; their ocular surface findings were very similar to those of
SJS/TEN patients. No EP3 protein was detected in conjunctival
epithelium from any of these patients (Fig. 3A), nor in conjunctival
epithelium from a GVHD patient with severe conjunctival
invasion to the cornea (Fig. 3B). When we assessed tissues from
patients with pterygium (Fig. 3C), or pseudo-OCP (Fig. 3D), we
detected EP3 protein in the conjunctival epithelium of pterygium
patients as we did in the control conjunctival epithelium from a
patient with conjunctivochalasis. EP3 protein was also present in
conjunctival epithelium from patients with pseudo-OCP although
it appeared to be slightly down-regulated. We also found EP3
protein in the conjunctival epithelium of a patient with giant
papillae due to chronic allergic keratoconjunctivitis (Fig. 3E). In
Table 1 we show the scores obtained by our evaluation of the
staining intensity and degree of down-regulation for all samples.
We document that EP3 was expressed in conjunctival
epithelium of patients with chemical eye burns and Mooren’s
ulcer and in normal human conjunctival epithelium. It was
markedly down-regulated in the conjunctival epithelium of SJS/
TEN- and OCP patients. Although we had only one patient each
with severe GVHD, pterygium, pseudo-OCP, and chronic allergic
keratoconjunctivitis, study of these samples suggested that EP3 is
expressed in the conjunctival epithelium of patients with
pterygium, pseudo-OCP, and chronic allergic keratoconjunctivitis,
and that EP3 might be greatly down-regulated in the conjunctival
epithelium of patients with severe GVHD.
Regarding in conjunctival epithelium, the expression of EP3
protein in the SJS/TEN and OCP patients was markedly
decreased compared with normal conjunctiva. However, its
expression in sub-conjunctival tissues may be up-regulated in
Figure 3. Immunohistological analysis of prostaglandin E receptor subtype EP3 in the conjunctival epithelium of patients with OCP
(A), severe GVHD (B), pterygium (C), pseudo-OCP (D), and a giant papilla due to allergic vernal conjunctivitis (E). The 3
rd lane shows
the ocular surface of patients. Each scale bar represents a length of 100 mm.
doi:10.1371/journal.pone.0025209.g003
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protein could be increased due to the presence of inflammatory
infiltrating cells in sub-conjunctival tissues (Fig. S2).
Discussion
We previously reported that in Japanese SJS/TEN patients
there was a significant association between severe ocular surface
complications and prostaglandin E receptor 3 gene (PTGER3)
polymorphisms and that compared to the controls, EP3 expression
was greatly reduced in their conjunctival epithelium [3]. Here we
studied keratinized and non-keratinized conjunctival epithelia of
SJS/TEN patients and the conjunctival epithelium of an SJS/
TEN patient whose ocular sequelae were minor (dry eye). We
found that EP3 was markedly down-regulated not only in
keratinized- but also in non-keratinized conjunctival epithelia
and even in the normal conjunctiva of a patient in the chronic
stage of SJS whose only ocular sequela was dry eye. Our results
suggest that the strong down-regulation of EP3 in conjunctival
epithelium of SJS/TEN patients is associated with the pathogen-
esis and pathology of the disease because PTGER3 (EP3)
polymorphisms are significantly associated with SJS/TEN.
Severe chemical eye burn results in conjunctival invasion into
the cornea due to a deficiency in corneal epithelial stem cells; this
leads to devastating ocular surface disorders similar to SJS/TEN.
However, EP3 was not down-regulated in the conjunctival
epithelium of patients with severe chemical eye burns, suggesting
that the pathology of the ocular surface changes was not associated
with EP3 expression.
In patients with Mooren’s ulcer the peripheral stroma is
destroyed first circumferentially then centrally, resulting in the
characteristic overhanging inner edge. This is an inflammatory
disease of the ocular surface that may require resection of the
inflammatory conjunctiva adjacent to the ulcer. We found that the
conjunctival epithelium of the inflammatory conjunctival tissues
adjacent to the ulcer clearly expressed EP3 protein, indicating that
other factors besides inflammation are required for a marked
down-regulation of EP3 expression.
OCP is a subset of mucous membrane pemphigoid. It is
characterized by the abnormal production of circulating autoan-
tibodies directed against various components of the basement
membrane zone and the generation of proinflammatory and
fibrogenic cytokines [8]. We found that, as in SJS/TEN patients,
EP3 was markedly down-regulated in the conjunctival epithelium
of OCP patients with conjunctival invasion to the cornea. As in
OCP patients, we failed to detect EP3 protein in the conjunctival
epithelium of a patient with severe GVHD with conjunctival
invasion to the cornea. This suggests that in a common
mechanism(s) may underlie the pathology of SJS/TEN and
OCP, especially in ocular surface epithelium such as the
conjunctival epithelium. EP3 expression has been reported in skin
and PGE2 was produced abundantly during skin allergic
Table 1. Staining-intensity score of conjunctival epithelium.
Picture Figure No Intensity score Down-regulation score Disease
Figure 1 A1 14 Nearly normal conjunctival tissues from conjunctival chalasis
A2 14
A3 14
B1 12 Normal conjunctival tissues
C1 7 ++ Keratinized conjunctival epithelium from SJS/TEN patients in the chronic stage
C2 7 ++
C3 6 ++
C4 7 ++
D1 5 ++ Non-keratinized conjunctival epithelium from SJS/TEN patients in the sub-acute stage
D2 5 ++
E5 ++ Non-keratinized conjunctival epithelium from SJS/TEN patients in the chronic stage
F5 ++ Conjunctival epithelium from an SJS/TEN patient manifesting only dry eye
Figure 2 A1 9 + Chemical eye burn
A2 16
A3 13
B1 12 Mooren’s ulcer
B2 12
B3 14
B4 10 +
Figure 3 A1 6 ++ Ocular cicatricial pemphigoid (OCP)
A2 6 ++
A3 6 ++
B6 ++ GVHD with severe conjunctival invasion to the cornea
C 13 Pterygium
D1 0 + Pseudo-OCP
E 16 Chronic allergic keratoconjunctivitis
doi:10.1371/journal.pone.0025209.t001
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decreased EP3 expression and the increased production of
cornified proteins in SJS/TEN and OCP.
We found that EP3 was clearly expressed in the conjunctival
epithelium of our patients with pterygium, pseudo-OCP, and a
giant papilla of allergic vernal conjunctivitis. Interestingly, the
expression of EP3 in conjunctival epithelium from patients with
OCP and pseudo-OCP was different: EP3 was clearly present in
the patient with pseudo-OCP but not the patient with OCP. The
patient with pseudo-OCP had received long-term treatment with
eye drops for glaucoma; this resulted in a deficiency of corneal
epithelial stem cells and led to conjunctival invasion into the
cornea. This suggests that different mechanisms are involved in the
expression of EP3. We also detected EP3 in the conjunctival
epithelium of the patient with allergic vernal conjunctivitis.
Elsewhere we documented that PGE2 acts as a ligand for EP3 in
the conjunctival epithelium and down-regulates the progression of
murine experimental allergic conjunctivitis [6]. Although EP3 may
down-regulate allergic reactions in patients with allergic conjunc-
tivitis, its loss may not be a causative factor.
In summary, EP3 is expressed not only in normal human
conjunctival epithelium but also in the conjunctival epithelium of
patients with chemical eye burns and Mooren’s ulcer. On the
other hand, it is markedly down-regulated in the conjunctival
epithelium of SJS/TEN- and OCP patients.
Supporting Information
Figure S1 The rabbit polyclonal antibody to EP3 we
used is checked and confirmed the EP3 specificity of this
antibody using immunoblot analysis.
(TIF)
Figure S2 EP3 expression in sub-conjunctival tissues in
a SJS/TEN patient in the chronic stage. In some instances
of SJS/TEN patients, vascular endothelia expressing the EP3
protein are found.
(TIF)
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